Otonomy Announces OTIVIDEX™ Data Presentation at American Academy of Otolaryngology - Head and Neck Surgery Foundation Annual Meeting
02 oct. 2018 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced that...
Otonomy to Present at Cantor Fitzgerald Global Healthcare Conference
25 sept. 2018 16h05 HE
|
Otonomy, Inc.
SAN DIEGO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced that...
Otonomy Announces OTIPRIO® Co-Promotion Agreement with Mission Pharmacal for Acute Otitis Externa Indication
06 août 2018 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced the...
Otonomy Initiates Phase 3 Clinical Trial of OTIVIDEX™ in Ménière’s Disease
26 juil. 2018 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, July 26, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced initiation...
Otonomy Reports First Quarter 2018 Financial Results and Provides Corporate Update
09 mai 2018 16h20 HE
|
Otonomy, Inc.
SAN DIEGO, May 09, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today reported financial...
Otonomy to Report First Quarter 2018 Financial Results and Provide Corporate Update
02 mai 2018 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, May 02, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced it will...
Otonomy Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
08 mars 2018 16h24 HE
|
Otonomy, Inc.
Type C meeting completed with FDA for OTIVIDEX™ in Ménière’s disease Consistent with prior guidance, pivotal trial for OTIVIDEX to start mid-2018 Conference call and webcast today at 4:30 p.m. EST ...
Otonomy Announces Multiple Presentations for Hearing Loss and Tinnitus Programs at Upcoming Association for Research in Otolaryngology Meeting
06 févr. 2018 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced seven data...
ENT and Allergy Associates Adds Depth, Breadth, Experience and Expertise to its Otology/Neurotology Division
04 nov. 2016 15h12 HE
|
Ent and Allergy
TARRYTOWN, N.Y., Nov. 4, 2016 (GLOBE NEWSWIRE) -- ENT and Allergy Associates, LLP (ENTA) is extremely proud and delighted to announce that Dr. Eric Smouha, currently Director of Otology and Neurology...
ENT and Allergy Associates(R) Sends Sound Waves through Middlesex County
20 avr. 2016 08h25 HE
|
Ent and Allergy
TARRYTOWN, N.Y., April 20, 2016 (GLOBE NEWSWIRE) -- Hearing loss and other diseases of the ear affect approximately 50 million Americans of all ages nationwide, including in the state of New...